The board of directors of pharmaceutical company Allergan plc (NYSE:AGN) declared dividend of USD0.74 per ordinary share for the fourth quarter of 2019, the company revealed on Friday.
This cash dividend is payable on 13 December 2019 to shareholders of record at the close of business as of 13 November 2019.
Headquartered in Dublin, Ireland, Allergan is focused on developing, manufacturing and commercialising branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
In addition, the company markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials